Clinical trial
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV…
NCT00471887 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00471887 |
|---|---|
| Title | Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma |
| Official title | A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | CP-675, 206 |
| Enrollment | 32 |
| Start date | Jan 1, 2007 |
| Primary completion | Jul 1, 2011 |
| Completion | Mar 1, 2015 |
| First posted | May 10, 2007 |
| Last update posted | Oct 26, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: